Caplin Steriles Ltd inks private label distribution pact with Xellia Pharmaceuticals

Caplin Steriles Limited, a subsidiary of Caplin Point Laboratories Ltd announced on Tuesday that it has entered into a private label distribution agreement with a speciality pharmaceutical company, Xellia Pharmaceuticals.

Caplin Point Laboratories has an agreement for five generic injectable abbreviated new drug application (ANDAs) in the US, of which, the first product is expected to launch soon. The company is yet to receive approval for remaining products, which is expected to come in a year or so.

The ANDAs are under the name of Caplin Steriles, while Xellia Pharmaceuticals will be commercialising them in the United States.

Caplin Steriles Limited is a niche sterile product manufacturing company, which is approved by United States Food and Drug Administration (USFDA) and European Union Good Manufacturing Services (EU-GMP). It has filed 18 ANDAs so far, along with nine approvals. Besides, it also has a larger pipeline of more than 35 ANDAs, which it expects to file within four years.

At 1.26 pm on Tuesday, the stock of Caplin Point Laboratories was trading at Rs 349.00 apiece with a growth of 2.45 per cent. It has a 52-week high of Rs 456 and a 52-week low of Rs 180 on BSE.